Celleration Appoints Mark T. Wagner President and Chief Executive Officer

"We are delighted by the addition of Mark to the Celleration team," said Ed Spencer, Jr., Chairman of Affinity Capital Management and Chairman of Celleration's board of directors. "Mark brings a wealth of experience and a solid history of building companies and delivering results. We are absolutely confident in Mark's ability to take Celleration to its next stage of commercialization and build value for its shareholders."

Mr. Wagner has decades of leadership experience in the medical device field. Most recently, he co-founded and is Board Chairman of Orasi Medical, a spinout from the University of Minnesota that is developing a diagnostic tool for neurological diseases. Prior to co-founding Orasi, Wagner served as CEO at multiple companies including, ProVation Medical, Survivalink and Altiva. Over the course of his career, Mr. Wagner has held positions of Vice President and General Manager of Nellcor's Global Sleep Solutions Group and executive positions with GE Medical Systems. Mr. Wagner currently serves on the board of directors of BioMedix Inc. and Vital Medix. Mr. Wagner holds a BS in Business Administration from the University of Southern California.

Kevin Nickels, the previous CEO, will continue to serve as the Chief Technology and Business Development Officer. Mr. Spencer commented, "During his seven years as CEO, Kevin made a huge contribution to the development of the business and I am delighted that we will continue to have the benefit of his vision in his new role as Chief Technology and Business Development Officer."

About Celleration, Inc.:

Celleration, Inc., a privately held medical device company, was founded in 1999 to develop and commercialize its therapeutic ultrasound platform. The patented MIST Technology delivers non-contact, low-frequency, low-intensity ultrasound to the patient's injured soft tissue in a painless fashion. The chronic diabetic foot ulcer market had been the Company's initial focus. MIST Therapy(R) has since expanded to various hard to heal, chronic wounds benefiting from higher incidence of complete healing in less time than standard of care. The end results, improving patient outcomes at a lower cost to the health care industry. In addition to the Company's prospective, randomized, double-blind, sham-controlled multi-center study in diabetic foot ulcers, which resulted in a statistically significant improvement in the rate of wound closure and time to wound closure, numerous independent clinical researchers without funding from the Company has further validated this value proposition.

    Contacts:
    Chris Geyen, Chief Financial Officer
    952-224-8700

    Richard Lewis Communications, Inc.
    212-827-0020
    Andrew Mielach, Media
    amielach@rlcinc.com
    Cecelia Heer, Investors
    cheer@rlcinc.com

SOURCE Celleration, Inc.

Copyright © 2009, PRNewswire
Copyright © 2009, NewsBlaze, Daily News

Tags: ,HEA,MEQ,PER,MN-Celleration-Appts